For Julie Steenhuysen's latest contributions to The Japan Times, see below:
Emergence of the same few mutations simultaneously in different parts of the world gives scientists cautious optimism that there may be limits on the pandemic's endurance.
Vaccine breakthroughs had initially sparked hope that the virus could be largely contained, but data on new variants has undercut that optimism.
The efforts rely on grassroots partners such as churches and health centers, and aim to topple long-standing barriers that keep minorities from participating in trials.
After developing and rolling out COVID-19 vaccines at record speed, drugmakers are already facing variants of the rapidly-evolving coronavirus that may render them ineffective.
Researchers were asked to tackle something that had never been done before: design a vaccine to stop a pandemic in its tracks in less than a year.
High-profile COVID-19 vaccines developed in Russia and China share a potential shortcoming: They are based on a common cold virus that many people have been exposed to, potentially limiting their effectiveness, some experts say. CanSino Biologics' vaccine, approved for military use in China, is a ...
A new vaccine for the dengue virus is taking a potentially risky road to prevent the mosquito-borne disease that infects nearly 400 million people each year. Takeda Pharmaceutical Co. plans to seek approval for the experimental vaccine first in countries where the virus is endemic, ...
Dr. Anthony Fauci doesn't get too excited about the results of animal studies, and he doesn't make house calls. But when a drug already taken by thousands of people for intestinal conditions appeared to control the monkey version of HIV, it got the attention of ...
Drug manufacturers have begun amassing enormous troves of human DNA in hopes of significantly shortening the time it takes to identify new drug candidates, a move some say is transforming the development of medicines. The efforts will help researchers identify rare genetic mutations by scanning ...
For months, Vanderbilt University researcher Dr. James Crowe has been desperately seeking access to the blood of U.S. Ebola survivors, hoping to extract the proteins that helped them overcome the deadly virus for use in new, potent drugs. His efforts finally paid off in mid-November ...
